Ionis Pharmaceuticals Stock News

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

CARLSBAD, Calif., Jan. 5, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration approved Xeris Bio

AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.

AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) shares, rose in value on Friday, 12/17/21, with the stock price up by 7.95% to the previous days close as strong demand from buyers drove the stock to $32.46. Actively observing the price movement in the last trading, the stock closed the session at $30.07, falling within a range of $29.60 Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Is A Blank Check For Growth Read More »

Ionis Pharmaceuticals (NASDAQ:IONS) had its price objective trimmed by SVB Leerink from $36.00 to $34.00 in a research note issued to investors on Friday, Analyst Price Targets reports. The firm currently has a market perform rating on the stock. Other equities analysts have also recently issued reports about the company. Needham & Company LLC cut []

Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 30.8% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 685,660 shares of the companys stock after purchasing an additional 161,334 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.s holdings in Ionis Pharmaceuticals were worth $22,997,000 as of []

Ionis is currently trading at $29.79. The intrinsic value of this stock is $49.27 and has more than a dozen clinical studies underway for Antisense Oligonucleotide Therapies.

Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by William Blair from a market perform rating to an outperform rating in a note issued to investors on Tuesday, The Fly reports. Other equities analysts have also issued reports about the company. BMO Capital Markets initiated coverage on Ionis Pharmaceuticals in a research note on Friday. They issued a []

Antisense & RNAi Therapeutics Market 2021 report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market- driven results deriving feasibility studies for client needs. Market Insights

Global Retirement Partners LLC boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 8.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 5,784 shares of the companys stock after acquiring an additional 471 shares during the period. Global Retirement Partners LLCs holdings in Ionis Pharmaceuticals []

BMO Capital Markets began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS) in a report released on Friday, PriceTargets.com reports. The firm issued a buy rating and a $65.00 target price on the stock. A number of other equities research analysts also recently commented on IONS. Needham & Company LLC reduced their target price on Ionis []

RNA based mostly medicine Market has garnered vital attention within the recent years because of its potential to treat type of chronic diseases like cancer, diabetes, AIDS, infectious disease and sure vas conditions. RNA Based Therapeutics Market is expected to garner